Published in Gastroenterology on September 06, 2012
New insights into pancreatic cancer-induced paraneoplastic diabetes. Nat Rev Gastroenterol Hepatol (2013) 1.54
Pancreatitis-diabetes-pancreatic cancer: summary of an NIDDK-NCI workshop. Pancreas (2013) 1.15
New-onset type 2 diabetes, elevated HbA1c, anti-diabetic medications, and risk of pancreatic cancer. Br J Cancer (2015) 1.04
Pancreatic Cancer-Derived Exosomes Cause Paraneoplastic β-cell Dysfunction. Clin Cancer Res (2014) 0.98
Emerging concepts in pancreatic cancer medicine: targeting the tumor stroma. Onco Targets Ther (2013) 0.95
Diabetes, pancreatic cancer, and metformin therapy. Front Physiol (2014) 0.92
Potential applications of nanotechnology for the diagnosis and treatment of pancreatic cancer. Front Physiol (2014) 0.90
Pathogenesis of pancreatic cancer exosome-induced lipolysis in adipose tissue. Gut (2015) 0.90
Macrophage migration inhibitory factor is overexpressed in pancreatic cancer tissues and impairs insulin secretion function of β-cell. J Transl Med (2014) 0.88
Adrenomedullin and tumour microenvironment. J Transl Med (2014) 0.88
Pancreatic Cancer Metabolism: Breaking It Down to Build It Back Up. Cancer Discov (2015) 0.83
Glycemic Change After Pancreaticoduodenectomy: A Population-Based Study. Medicine (Baltimore) (2015) 0.81
Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus. Clin Cancer Res (2015) 0.79
Baseline hemoglobin-A1c impacts clinical outcomes in patients with pancreatic cancer. J Natl Compr Canc Netw (2014) 0.79
Effects of Obesity and Diabetes on α- and β-Cell Mass in Surgically Resected Human Pancreas. J Clin Endocrinol Metab (2016) 0.79
Pancreatic cancer-improved care achievable. World J Gastroenterol (2014) 0.79
Diabetes mellitus and pancreatic cancer: why the association matters? Pancreas (2013) 0.78
Adrenomedullin promotes intrahepatic cholangiocellular carcinoma metastasis and invasion by inducing epithelial-mesenchymal transition. Oncol Rep (2015) 0.76
Hypothesis: solid tumours behave as systemic metabolic dictators. J Cell Mol Med (2016) 0.76
Pancreatic cancer presenting as new-onset diabetes. Case Rep Oncol (2014) 0.75
Reply to 'Comment on 'New-onset type 2 diabetes, elevated HbA1c, anti-diabetic medications, and risk of pancreatic cancer''. Br J Cancer (2016) 0.75
MYB Promotes Desmoplasia in Pancreatic Cancer through Direct Transcriptional Up-regulation and Cooperative Action of Sonic Hedgehog and Adrenomedullin. J Biol Chem (2016) 0.75
Increased serum levels of betatrophin in pancreatic cancer-associated diabetes. Oncotarget (2016) 0.75
The impact of diabetes mellitus on survival following resection and adjuvant chemotherapy for pancreatic cancer. Br J Cancer (2016) 0.75
Pancreatic Cancer Screening. Curr Treat Options Gastroenterol (2017) 0.75
Diabetes and the Pancreatobiliary Diseases. Curr Treat Options Gastroenterol (2017) 0.75
Pancreatic Cancer Heralded by Worsening Glycemic Control: A Report of Two Cases. J Investig Med High Impact Case Rep (2017) 0.75
Diabetes and the risk of pancreatic cancer. N Engl J Med (1994) 3.78
Pancreatic cancer-associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer. Gastroenterology (2007) 3.20
Probability of pancreatic cancer following diabetes: a population-based study. Gastroenterology (2005) 2.60
Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus. Gastroenterology (2008) 2.58
Improved glucose metabolism after subtotal pancreatectomy for pancreatic cancer. Br J Surg (1993) 1.62
Pancreatic cancer is associated with impaired glucose metabolism. Eur J Surg (1993) 1.57
Detecting early pancreatic cancer: problems and prospects. Semin Oncol (2007) 1.54
A prospective study of glucose tolerance, insulin, C-peptide, and glucagon responses in patients with pancreatic carcinoma. Am J Dig Dis (1978) 1.51
The prognostic and predictive value of serum CA19.9 in pancreatic cancer. Ann Oncol (2012) 1.46
Insulin secretion and action in patients with pancreatic cancer. Cancer (1991) 1.41
Biomarkers for the prediction of type 2 diabetes and cardiovascular disease. Clin Pharmacol Ther (2011) 1.41
Islet amyloid polypeptide is not a satisfactory marker for detecting pancreatic cancer. Gastroenterology (2001) 1.35
A prospective pancreatographic study of the prevalence of pancreatic carcinoma in patients with diabetes mellitus. Cancer (2002) 1.27
The effects of adrenomedullin overexpression in breast tumor cells. J Natl Cancer Inst (2002) 1.26
Is profound peripheral insulin resistance in patients with pancreatic cancer caused by a tumor-associated factor? Am J Surg (1993) 1.25
Should pancreas imaging be recommanded in patients over 50 years when diabetes is discovered because of acute symptoms? Diabetes Metab (2004) 1.22
Putative pancreatic cancer-associated diabetogenic factor: 2030 MW peptide. Pancreas (2002) 1.22
Receptor activity-modifying proteins: RAMPing up adrenomedullin signaling. Mol Endocrinol (2006) 1.19
Dissociated secretion of islet amyloid polypeptide and insulin in serum-free culture media conditioned by human pancreatic adenocarcinoma cell lines. Int J Pancreatol (1997) 1.17
Adrenomedullin is expressed in pancreatic cancer and stimulates cell proliferation and invasion in an autocrine manner via the adrenomedullin receptor, ADMR. Cancer Res (2007) 1.17
Islet amyloid polypeptide in patients with pancreatic cancer and diabetes. N Engl J Med (1994) 1.14
Regulation of insulin secretion and blood glucose metabolism by adrenomedullin. Endocrinology (1996) 1.12
The relationship between adrenomedullin, metabolic factors, and vascular function in individuals with type 2 diabetes. Diabetes Care (2007) 1.07
Islet hormone secretion in pancreatic cancer patients with diabetes. Pancreas (1997) 1.06
The pharmacology of adrenomedullin 2/intermedin. Br J Pharmacol (2012) 1.05
Beta-cell function and insulin resistance evaluated by HOMA in pancreatic cancer subjects with varying degrees of glucose intolerance. Pancreatology (2005) 0.98
Beta-cell function in pancreatic adenocarcinoma. Pancreas (1994) 0.95
Impaired insulin action on phosphatidylinositol 3-kinase activity and glucose transport in skeletal muscle of pancreatic cancer patients. Pancreas (2003) 0.94
Adrenomedullin and pregnancy: perspectives from animal models to humans. Trends Endocrinol Metab (2012) 0.94
Plasma adrenomedullin in diabetes. Lancet (1997) 0.93
Abnormal insulin secretion in carcinoma of the pancreas: response to glucagon stimulation. Diabet Med (1985) 0.93
Glucose tolerance and insulin secretion in experimental pancreatic cancer in the Syrian hamster. Res Exp Med (Berl) (1993) 0.93
Weight loss precedes cancer-specific symptoms in pancreatic cancer-associated diabetes mellitus. Pancreas (2011) 0.91
Glucose metabolic alterations in isolated and perfused rat hepatocytes induced by pancreatic cancer conditioned medium: a low molecular weight factor possibly involved. Biochem Biophys Res Commun (1999) 0.90
Is adrenomedullin a causal agent in some cases of type 2 diabetes? Peptides (1999) 0.86
Dissociated insulin and islet amyloid polypeptide secretion from isolated rat pancreatic islets cocultured with human pancreatic adenocarcinoma cells. Pancreas (1999) 0.85
Regulation of pancreatic physiology by adrenomedullin and its binding protein. Regul Pept (2003) 0.83
A genetic variant in the gene encoding adrenomedullin predicts the development of dysglycemia over 6.4 years in Chinese. Clin Chim Acta (2010) 0.82
Adrenomedullin inhibits insulin exocytosis via pertussis toxin-sensitive G protein-coupled mechanism. Am J Physiol Endocrinol Metab (2006) 0.81
Bioinformatics methods for prioritizing serum biomarker candidates. Clin Chem (2006) 0.80
Molecular forms of plasma and urinary adrenomedullin in normal, essential hypertension and chronic renal failure. J Hypertens (2001) 0.79
Adrenomedullin as a sensitive marker for coronary and peripheral arterial complications in patients with atherosclerotic risks. Peptides (2004) 0.77
International network of cancer genome projects. Nature (2010) 20.35
Managing incidental findings and research results in genomic research involving biobanks and archived data sets. Genet Med (2012) 9.65
Consensus statement on the pathology of IgG4-related disease. Mod Pathol (2012) 9.01
Genome partitioning of genetic variation for complex traits using common SNPs. Nat Genet (2011) 8.57
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature (2012) 8.31
DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med (2006) 7.90
High-resolution whole-genome association study of Parkinson disease. Am J Hum Genet (2005) 6.86
Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. J Clin Oncol (2002) 5.91
New loci associated with kidney function and chronic kidney disease. Nat Genet (2010) 5.58
Cancer-associated stromal fibroblasts promote pancreatic tumor progression. Cancer Res (2008) 5.21
Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat Genet (2009) 5.14
A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nat Genet (2010) 4.89
Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. JAMA (2006) 4.87
GWAS of 126,559 individuals identifies genetic variants associated with educational attainment. Science (2013) 4.71
Diagnosis of autoimmune pancreatitis: the Mayo Clinic experience. Clin Gastroenterol Hepatol (2006) 4.70
International consensus diagnostic criteria for autoimmune pancreatitis: guidelines of the International Association of Pancreatology. Pancreas (2011) 4.56
A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance. Nat Genet (2012) 4.37
Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. Gastroenterology (2007) 4.33
Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer. Cancer Res (2003) 4.30
Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease. JAMA (2006) 4.26
Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. Clin Gastroenterol Hepatol (2006) 4.22
Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res (2009) 4.19
Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X. JAMA (2005) 3.99
Variants near FOXE1 are associated with hypothyroidism and other thyroid conditions: using electronic medical records for genome- and phenome-wide studies. Am J Hum Genet (2011) 3.85
Survival patterns after oophorectomy in premenopausal women: a population-based cohort study. Lancet Oncol (2006) 3.81
Detectable clonal mosaicism from birth to old age and its relationship to cancer. Nat Genet (2012) 3.68
Genetic variants and risk of lung cancer in never smokers: a genome-wide association study. Lancet Oncol (2010) 3.49
Idiopathic chronic pancreatitis with periductal lymphoplasmacytic infiltration: clinicopathologic features of 35 cases. Am J Surg Pathol (2003) 3.36
Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res (2004) 3.31
A genomic pathway approach to a complex disease: axon guidance and Parkinson disease. PLoS Genet (2007) 3.28
ATM mutations in patients with hereditary pancreatic cancer. Cancer Discov (2011) 3.27
Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol (2009) 3.26
Differences in clinical profile and relapse rate of type 1 versus type 2 autoimmune pancreatitis. Gastroenterology (2010) 3.24
Pancreatic cancer-associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer. Gastroenterology (2007) 3.20
Primary chemoprevention of familial adenomatous polyposis with sulindac. N Engl J Med (2002) 3.16
Sclerosing mesenteritis: clinical features, treatment, and outcome in ninety-two patients. Clin Gastroenterol Hepatol (2007) 3.14
Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach. Clin Gastroenterol Hepatol (2004) 3.10
New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer. Lancet Oncol (2009) 2.92
Risk of intestinal cancer in inflammatory bowel disease: a population-based study from olmsted county, Minnesota. Gastroenterology (2006) 2.87
Absolute quantification of the model biomarker prostate-specific antigen in serum by LC-Ms/MS using protein cleavage and isotope dilution mass spectrometry. J Proteome Res (2004) 2.85
Surgically managed gastrointestinal stromal tumors: a comparative and prognostic analysis. Ann Surg Oncol (2007) 2.82
Study of recurrence after surgical resection of intraductal papillary mucinous neoplasm of the pancreas. Gastroenterology (2002) 2.76
Value of serum IgG4 in the diagnosis of autoimmune pancreatitis and in distinguishing it from pancreatic cancer. Am J Gastroenterol (2007) 2.73
Glycogen synthase kinase-3beta participates in nuclear factor kappaB-mediated gene transcription and cell survival in pancreatic cancer cells. Cancer Res (2005) 2.72
CUBN is a gene locus for albuminuria. J Am Soc Nephrol (2011) 2.70
Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma: is cure possible? Ann Surg (2008) 2.66
Impact of multiple transarterial chemoembolization treatments on hepatocellular carcinoma for patients awaiting liver transplantation. Liver Transpl (2015) 2.63
Probability of pancreatic cancer following diabetes: a population-based study. Gastroenterology (2005) 2.60
Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus. Gastroenterology (2008) 2.58
Epidemiology of eosinophilic esophagitis over three decades in Olmsted County, Minnesota. Clin Gastroenterol Hepatol (2009) 2.55
Mutations in ribonucleic acid binding protein gene cause familial dilated cardiomyopathy. J Am Coll Cardiol (2009) 2.53
Mechanisms of the age-associated deterioration in glucose tolerance: contribution of alterations in insulin secretion, action, and clearance. Diabetes (2003) 2.53
Long-term outcomes of autoimmune pancreatitis: a multicentre, international analysis. Gut (2012) 2.52
Quality control procedures for genome-wide association studies. Curr Protoc Hum Genet (2011) 2.48
National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem (2008) 2.44
The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. Hepatology (2011) 2.42
AKT proto-oncogene overexpression is an early event during sporadic colon carcinogenesis. Carcinogenesis (2002) 2.41
Cigarette smoking and colorectal cancer risk by molecularly defined subtypes. J Natl Cancer Inst (2010) 2.38
Therapeutic targeting of neuropilin-2 on colorectal carcinoma cells implanted in the murine liver. J Natl Cancer Inst (2008) 2.37
MYH mutations in patients with attenuated and classic polyposis and with young-onset colorectal cancer without polyps. Gastroenterology (2004) 2.35
Cellular changes in diabetic and idiopathic gastroparesis. Gastroenterology (2011) 2.30
Transcriptional suppression of mir-29b-1/mir-29a promoter by c-Myc, hedgehog, and NF-kappaB. J Cell Biochem (2010) 2.30
Endoscopic retrograde pancreatography criteria to diagnose autoimmune pancreatitis: an international multicentre study. Gut (2010) 2.29
Membranous glomerulonephritis is a manifestation of IgG4-related disease. Kidney Int (2012) 2.28
Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%. Cancer Res (2002) 2.23
Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent. Cancer Res (2008) 2.20
National Institutes of Health Consensus Development Conference Statement: management of hepatitis B. Ann Intern Med (2009) 2.19
Serologic issues in IgG4-related systemic disease and autoimmune pancreatitis. Curr Opin Rheumatol (2011) 2.17
Ras activity levels control the development of pancreatic diseases. Gastroenterology (2009) 2.17
Mitochondrial DNA content: its genetic heritability and association with renal cell carcinoma. J Natl Cancer Inst (2008) 2.17
Familial aggregation of common sequence variants on 15q24-25.1 in lung cancer. J Natl Cancer Inst (2008) 2.15
Resectability of presymptomatic pancreatic cancer and its relationship to onset of diabetes: a retrospective review of CT scans and fasting glucose values prior to diagnosis. Am J Gastroenterol (2007) 2.15
Telomere length varies by DNA extraction method: implications for epidemiologic research. Cancer Epidemiol Biomarkers Prev (2013) 2.14
Atrial natriuretic peptide frameshift mutation in familial atrial fibrillation. N Engl J Med (2008) 2.14
Prevalence and predictive factors of eosinophilic esophagitis in patients presenting with dysphagia: a prospective study. Am J Gastroenterol (2007) 2.14
An NF-κB pathway-mediated positive feedback loop amplifies Ras activity to pathological levels in mice. J Clin Invest (2012) 2.13
Direct evidence for endothelial vascular endothelial growth factor receptor-1 function in nitric oxide-mediated angiogenesis. Circ Res (2006) 2.12
3' tag digital gene expression profiling of human brain and universal reference RNA using Illumina Genome Analyzer. BMC Genomics (2009) 2.12
Measurement and quality control issues in multiplex protein assays: a case study. Clin Chem (2009) 2.11